On Demand Session ⁽¹⁷⁾

Clinical Trial Design

This session focuses on the basics required for study design and outcome measures.

More Top Abstracts

This session consists of highly ranked abstracts that were not accepted for a late-breaking abstract presentation. However, their research is important. The topics include DRG, SCS, and non-invasive forms of stimulation.

Advanced Practice Provider

Advanced Practice Providers are an integral part of neuromodulation practices around the world, and their role needs to be supported through education in their field, training on the application of their skill sets, and gaining insight on how to provide well-rounded care. Specifically, this session will provide tools to improve their practice in a multidisciplinary field.

Learning Objectives

• Describe the importance of performing and participating in research to track outcomes.
• Discuss barriers to the precertification process and apply methods to reduce the administrative burden.
• Identify and manage common infection issues in neuromodulation procedures.
• Recognize when neuromodulation is no longer appropriate and identify options for management and treatment.

Standardizing Patient Care: Importance of Tracking Your Outcomes

Brittney Misercola, APRN FNP-C CFRN LP

Navigating Through the Precertification Process

Teresita Devera, MSN CRNP ANP-BC

To Treat or Not to Treat: Management of Complications

Beth Parente, PA-C

When Do You Call It Quits and Options After Neuromodulation Therapy for Chronic Pain Fails

Ashley Comer, MSN APRN FNP-C

Psychiatry

Electroconvulsive therapy (ECT) is a long-standing treatment modality with demonstrated efficacy in addressing severe psychiatric illnesses, including major depressive disorder, bipolar disorder, schizophrenia, and psychotic depression. Unlike antidepressant medications, ECT is characterized by an acute time course of response, though benefits can deteriorate over time and carry a significant side effect profile, including memory impairment. This session will review the state-of-the-art in terms of electroconvulsive therapy for psychiatric disease and explore emerging research. 

Ketamine has recently attained FDA approval for the treatment of major depressive disorder that is refractory to other therapies. Unlike other medical antidepressant interventions, its effects are immediate and are being integrated into the therapeutic approach to acutely suicidal and destabilized patients. However, serious limitations to its therapeutic potential exist in the transient temporal profile of response, as well as in the potential for abuse. This session will also explore the role of Ketamine in the treatment of refractory psychiatric illness and the mechanistic implications of Ketamine therapy on our understanding of disease pathophysiology. 

Learning Objectives

• Summarize the use of modern applications of ECT therapy.
• Explain neuroimaging biomarkers that can predict treatment response to ECT.
• Identify recent advances in the use of intravenous and intranasal Ketamine for treatment-refractory depression.
• Discuss how advances in neurobiology and pharmacology have led to novel treatments for treatment-resistant depression.

Structural Plasticity of the Hippocampus and Amygdala Induced by Electroconvulsive Therapy in Major Depression

Amber M Leaver, PhD

Modern Applications: Unilateral Ultra-Brief Pulse ECT

Gregory Sahlem, MD

Pharmacological Mechanisms of Action of Ketamine and Therapeutic Considerations

Asim A Shah, MD

The Role of Ketamine in the Treatment-Resistant Depression Clinic

Patricio Riva Posse, MD